Reduced dimensions for effective use of space in a dosing rig, ideal for OEM applications. Pump protection: IP65.īoth wall or foot installations using the universal support bracket supplied with the pumps
#34446801 eutron series
It has proven reliability and quality and due to it compact design and versatility the PKX series is the ideal solution for many chemical dosing application where moderate flow rate is required with counter pressures up to 6 bar (87 psi).Īnti-acids mica-filled reinforced polypropylene material of enclosure.Įxcellent water resistant for tough applications. doi: 10.1016/j.ejca.2019.07.026.The PKX is a PTFE diaphragm type Solenoid Metering Pump that distinguishes itself for its simplicity of use. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: Results from the CCG-1961 randomised cohort trial. Dexamethasone in Hospitalized Patients with Covid-19.
Infection-related mortality in children with acute lymphoblastic leukemia: An analysis of infectious deaths on UKALL2003. Acute lymphoblastic leukemia in children. IP intraperitoneal, NV nanovectors, PI propidium iodide.
#34446801 eutron free
( E) Kaplan Meier survival analysis of ALL engrafted NSG (n = 9 per group), treated with Dex-NV (dashed line), free Dex (solid line) or placebo (grey line) IP. Vertical dotted lines indicate end of Dex treatment. Engraftment levels of individual mice (n = 3 per group) are shown. Once engraftment reached > 0.1%, mice were treated IP with Dex-NV (dashed coloured line), free Dex (solid coloured line) both at 2.5 mg/kg or placebo (grey line) 5 times per week over 28 days. 1–3, respectively, were inoculated into NSG mice and the levels of human cells (CD45 + and CD7 +) were measured in weekly PB aspirates. Data represent mean ± SD of at least 2 replicate measurements. Viability was assessed by flow cytometry using Annexin-V and PI, expressed as a proportion of the untreated control sample. 1–6) and normal bone marrow (NBM, n = 3) treated with Dex-NV (dashed lines) or free Dex (solid lines) for 48 h. The study describes a non-toxic, more easily scalable system for improving Dex solubility for use in cancer and can be applied to other medical conditions associated with inflammation.Įfficacy of Dex-NV in vitro and in vivo.
NV accumulated in major organs, including bone marrow and brain, known sanctuary sites for ALL. Broad distribution of NV was seen rapidly following inoculation into mice. Importantly, high levels of DMSO solvent were not required in the NV formulations. Dex-NV were just as effective as the free drug against primary human leukemia cells in vitro and in vivo. Non-toxic, fully biodegradable Dex loaded nanovectors (NV) were formulated, via simple direct hydration within 10 min, as a vehicle to extend exposure and distribution in vivo. Data from clinical trials indicates that the pharmacokinetics of Dex vary considerably between patients and prolonging drug exposure rather than increasing absolute dose may improve efficacy. Dexamethasone (Dex) is a highly insoluble front-line drug used in cancer therapy.
0 kommentar(er)
